ConductScience.org, home

Paper32004792

Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used.

Ogata D and 20 others. Eur J Cancer, 2020. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. Papers, record 32004792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32004792

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used.
PubMed
Journal
Eur J Cancer
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.9
iCite
Revised in PubMed
2020-07-31
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ogata DDai
2Namikawa KKenjiro
3Otsuka MMasaki
4Asai JJun
5Kato HHisoshi
6Yasuda MMasahito
7Maekawa TTakeo
8Fujimura TTaku
9Kato JJunji
10Takenouchi TTatsuya
11Nagase KKotaro
12Kawaguchi MMasakazu
13Kaji TTatsuya
14Kuwatsuka YYutaka
15Shibayama YYoshitsugu
16Takai TToshihiro
17Okumura MMao
18Kambayashi YYumi
19Yoshikawa SSyusuke
20Yamazaki NNaoya

Source PubMed

See all 21 authorsDownload CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, Squamous CellMajor topic
ChemoradiotherapyMajor topic
CisplatinMajor topic
RadiotherapyMajor topic
Skin NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate

Source PubMed

Download CSV of topics

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
41957579CDKN2A, ITGA3, SMAD4 and SIRT7 gene expression in human cutaneous squamous cell carcinoma development and pre-clinical diagnosis.BMC Cancer2026https://conductscience.org/library/papers/41957579PubMed
41681926A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.Cancers (Basel)2026https://conductscience.org/library/papers/41681926PubMed
39779554Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches.Curr Comput Aided Drug Des2026https://conductscience.org/library/papers/39779554PubMed
39582977KS-cSCC-1 and KS-cSCC-2: two novel cutaneous squamous cell carcinoma cell lines established from Japanese patients.Front Med (Lausanne)2024https://conductscience.org/library/papers/39582977PubMed
38756868Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review).Mol Clin Oncol2024https://conductscience.org/library/papers/38756868PubMed
36844955Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.Front Med (Lausanne)2022https://conductscience.org/library/papers/36844955PubMed
36012449A Hybrid Epithelial to Mesenchymal Transition in Ex Vivo Cutaneous Squamous Cell Carcinoma Tissues.Int J Mol Sci2022https://conductscience.org/library/papers/36012449PubMed
35454779Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy.Cancers (Basel)2022https://conductscience.org/library/papers/35454779PubMed
33925915Advances in Targeting Cutaneous Melanoma.Cancers (Basel)2021https://conductscience.org/library/papers/33925915PubMed
33558963An online review of informational sources for advanced or high-risk cutaneous squamous cell carcinoma.Support Care Cancer2021https://conductscience.org/library/papers/33558963PubMed
33126349Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).Medicine (Baltimore)2020https://conductscience.org/library/papers/33126349PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32004792

GET https://conductscience.org/api/papers/v1/32004792/authors?page=2